Last update 16 Apr 2025

SGN-ALPV

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
SGN ALPV, SGNALPV
Target
ALPP x ALPPL2 x Tubulin
Action
inhibitors
Mechanism
ALPP inhibitors(alkaline phosphatase, placental inhibitors), ALPPL2 inhibitors(alkaline phosphatase, germ cell inhibitors), Tubulin inhibitors
Therapeutic Areas
NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease+ [3]
Active Indication-
Inactive Indication
Advanced Malignant Solid NeoplasmGastroesophageal junction adenocarcinomaMetastatic endometrial cancer+ [4]
Originator Organization
Seagen, Inc.Seagen, Inc.
Active Organization-
Inactive Organization
Seagen, Inc.Seagen, Inc.
Drug Highest PhaseDiscontinuedPhase 1
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC11H22N4O4
InChIKeyAGGWFDNPHKLBBV-YUMQZZPRSA-N
CAS Registry159858-33-0
View All Structures (2)
Boost your research with our ADC technology data.
login
or
view full example data
Boost your research with our ADC technology data.

Related

1
Clinical Trials associated with SGN-ALPV
NCT05229900
/ TerminatedPhase 1
A Phase 1 Study of SGN-ALPV in Advanced Solid Tumors
100 Clinical Results associated with SGN-ALPV
Login to view more data
100 Translational Medicine associated with SGN-ALPV
Login to view more data
100 Patents (Medical) associated with SGN-ALPV
Login to view more data
100 Deals associated with SGN-ALPV
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Malignant Solid NeoplasmPhase 1
United States
Seagen, Inc.Seagen, Inc.
21 Apr 2022
Advanced Malignant Solid NeoplasmPhase 1
Canada
Seagen, Inc.Seagen, Inc.
21 Apr 2022
Advanced Malignant Solid NeoplasmPhase 1
Spain
Seagen, Inc.Seagen, Inc.
21 Apr 2022
Advanced Malignant Solid NeoplasmPhase 1
Sweden
Seagen, Inc.Seagen, Inc.
21 Apr 2022
Advanced Malignant Solid NeoplasmPhase 1
United Kingdom
Seagen, Inc.Seagen, Inc.
21 Apr 2022
Gastroesophageal junction adenocarcinomaPhase 1
United States
Seagen, Inc.Seagen, Inc.
21 Apr 2022
Gastroesophageal junction adenocarcinomaPhase 1
Canada
Seagen, Inc.Seagen, Inc.
21 Apr 2022
Gastroesophageal junction adenocarcinomaPhase 1
Spain
Seagen, Inc.Seagen, Inc.
21 Apr 2022
Gastroesophageal junction adenocarcinomaPhase 1
Sweden
Seagen, Inc.Seagen, Inc.
21 Apr 2022
Gastroesophageal junction adenocarcinomaPhase 1
United Kingdom
Seagen, Inc.Seagen, Inc.
21 Apr 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free